Graves’ disease, also known as thyrotoxicosis or toxic diffuse goiter, is an autoimmune disorder in which the thyroid gland is over-stimulated by the body's immune system to produce too much thyroid hormone. This causes an overactive thyroid or hyperthyroidism. The major symptoms of Graves' disease include rapid or irregular heartbeat, fatigue, weight loss, nervousness, wide-eyed appearance, and enlargement of the thyroid gland. Historically, Graves’ disease therapeutics market was dominated by antithyroid drugs and radioactive iodine therapy. However, in recent years targeted therapies are emerging as a promising approach to treat the root cause of the disease. The growing research and development in targeted drug therapy is anticipated to provide lucrative opportunities for Graves’ disease therapeutics market.
The global Graves' disease therapeutics market is estimated to be valued at US$ 570.2 million in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period of 2024 to 2031.
Key Takeaways
Key players:
- Key players operating in the Graves disease therapeutics market Insights are focusing on developing targeted drug therapies such as monoclonal antibodies that can potentially block the receptor sites and treat the underlying autoimmune cause of the disease.
Growing demand:
- Increasing healthcare expenditure and rising public awareness about Graves’ disease and available treatment options are expected to boost the demand for Graves’ disease therapeutics.
Technological advancements:
- Researchers are exploring various new therapeutic technologies such as RNA interference, which has potential to selectively block the messenger RNAs that encode thyrotropin receptor and treat the disease.
Market Trends
Targeted drug therapy: Majority of the clinical trials are evaluating targeted drug therapies such as monoclonal antibodies that can potentially block the receptor sites and treat the underlying autoimmune cause of the disease.
Precision medicine: Companies are exploring opportunities in areas of companion diagnostics, biomarkers and development of precision therapies to offer personalized treatment options to patients.
Market Opportunities
Untapped emerging markets: Emerging countries such as India, China, Brazil, Mexico hold huge market opportunities for Graves' disease therapeutics market players owing to rapidly growing patient pool and healthcare industry.
Strategic collaborations: Collaborations between drug developers, medical technology companies and clinical research organizations can help accelerate development and commercialization of novel Graves' disease treatment solutions.
Impact of COVID-19 on Graves Disease Overactive Thyroid Market
The COVID-19 pandemic has impacted the growth of the Graves disease overactive thyroid market. Several factors related to the pandemic have played a role. During the initial lockdown phases in 2020 and 2021, access to healthcare facilities was disrupted or delayed for non-COVID patients. This negatively impacted the diagnosis and treatment of Graves' disease cases. Several clinical trials related to new drug development were also halted or delayed.
However, as lockdowns have eased in 2022, the market is recovering. The demand for existing drug therapies has increased again as patients are now able to access healthcare. Telehealth and remote monitoring solutions have also helped maintain care for patients undergoing long-term treatment. Manufacturers are resuming halted clinical trials and expediting regulatory approvals for new drug therapies. The focus is now on developing therapies that can be self-administered by patients at home. This would help make treatment more accessible during any future healthcare disruptions.
Geographical Regions with High Market Concentration
In terms of value, North America currently holds the largest share of the global Graves Disease Overactive Thyroid Market Regional Analysis. This is primarily due to advanced healthcare infrastructure and higher diagnosis and treatment rates in the United States. Within North America, the US accounts for the majority of the region's market share.
Fastest Growing Region
Asia Pacific is expected to be the fastest growing regional market during the forecast period from 2024 to 2031. Improving access to healthcare facilities, rising medical expenditures, growing awareness about Graves' disease, and increasing focus on early diagnosis are some key factors driving the market in this region. China and India are expected to lead the market growth within Asia Pacific.
Get More Insights On Graves disease overactive thyroid market
· For Deeper Insights, Find the Report in the Language that You want.
About Author
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)